nach oben

The European Journal of Health Economics

Erschienen in:

01.02.2010 | Original Paper

An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?

verfasst von: Rachel A. Elliott, Helen L. A. Weatherly, Neil S. Hawkins, Gillian Cranny, Duncan Chambers, Lindsey Myers, Alison Eastwood, Mark J. Sculpher

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

Surgical site infection is commonly caused by Staphylococcus aureus. The multiresistant strains (MRSA) are resistant to most antibiotic prophylaxis regimens. Our aim was to explore whether there is a threshold of MRSA prevalence at which switching to routine glycopeptide-based antibiotic prophylaxis becomes cost-effective.

Methods

An indicative model was designed to explore the cost-effectiveness of vancomycin, cephalosporin or a combination, in patients undergoing primary hip arthroplasty.

Results

If the MRSA infection rate is equal to or above 0.25% and the rate of other infections with cephalosporin prophylaxis is equal to or above 0.2%, use of the combination antibiotic prophylaxis is optimal.

Discussion

Modelling the cost-effectiveness of interventions for MRSA prevention is complex due to uncertainty around resistance and effectiveness of glycopeptides.

Conclusions

The indicative model provides a framework for evaluation. More work is needed to understand the impact of antibiotic resistance over time in these currently effective antibiotics.

National Institute for Health and Clinical Excellence (NICE): Costing statement: surgical site infection: prevention and treatment of surgical site infection. http://www.nice.org.uk/nicemedia/pdf/CG74CostStatement2.pdf (2008). Accessed 1 Mar 2009

Coello, R., Charlett, A., Wilson, J., Ward, V., Pearson, A., Borriello, P.: Adverse impact of surgical site infections in English hospitals. J Hosp Infect 60(2), 93–103 (2005). doi:10.1016/j.jhin.2004.10.019 CrossRef

Scottish Intercollegiate Guidelines Network: Antibiotic prophylaxis in surgery. Scottish Intercollegiate Guidelines Network, editor. http://www.sign.ac.uk/guidelines/fulltext/45/index.html (2000). Edinburgh. Accessed 27 Jun 2007

Nosocomial Infection National Surveillance Service: Surveillance of surgical site infection in English hospitals 1997–2002. http://www.hpa.org.uk/infections/topics_az/hai/SSIreport.pdf (2002). London: Public Health Laboratory Service. Accessed 27 Jun 2007

Gemmell, C.G., Edwards, D.I., Fraise, A.P. et al.: Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. 57(589), 608 (2006)

Struelens, M.J.: The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. BMJ 317, 652–654 (1998)

Gemmell, C.G., Edwards, D.I., Fraise, A.P. et al.: Guidelines for the prophylaxis and treatment of meticillin (methicillin)-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. http://www.bsac.org.uk/_db/_documents/MRSA_treatment_consultation.pdf Accessed 1 Mar 2005

Chang, S., Sievert, D.M., Hageman, J.C., Boulton, M.L., Tenover, F.C., Downes, F.P.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348, 1342–1347 (2003). doi:10.1056/NEJMoa025025 CrossRef

Tenover, F.C., Biddle, J.W., Lancaster, M.V.: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7, 327–332 (2001)CrossRef

10.

Aucken, H.M., Ganner, M., Murchan, S., Cookson, B.D., Johnson, A.P.: A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J Antimicrob Chemother 50, 171–175 (2002). doi:10.1093/jac/dkf117 CrossRef

11.

Bertrand, X., Hocquet, D., Thouverez, M., Plesiat, P., Talon, D.: Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France. Eur J Clin Microbiol Infect Dis 22, 504–506 (2003). doi:10.1007/s10096-003-0966-7 CrossRef

12.

Mohaved, M.R., Kasravi, B., Bryan, C.S.: Prophylactic use of vancomycin in adult cardiology and cardiac surgery. J Cardiovasc Pharmacol Ther 9, 13–20 (2004). doi:10.1177/107424840400900i103 CrossRef

13.

Drummond, M., Sculpher, M.J., Torrance, G., O’Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)

14.

Cranny, G., Elliott, R.A., Weatherly, H., et al.: A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess 12, 1–200 (2008)

15.

Zanetti, G., Goldie, S.J., Platt, R.: Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 7, 820–827 (2001)CrossRef

16.

Rahman, M.H., Anson, J.: Peri-operative antibacterial prophylaxis. Pharm J 272, 743–745 (2004)

17.

British Orthopaedic Association: Total hip replacement: a guide to best practice. British Orthopaedic Association, London (1999)

18.

Department of Health: Bacteraemia surveillance scheme, MRSA bacteraemia by NHS Trust: table 2 data for each 6 months, 2001–2005. http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsStatistics/PublicationsStatisticsArticle/fs/en?CONTENT_ID=4085951&chk=HBt2QD (2005). Accessed 7 Nov 2005

19.

Ridgeway, S., Wilson, J., Charlet, A., Kafatos, G., Pearson, A., Coello, R.: Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br 87-B(6), 844–850 (2005). doi:10.1302/0301-620X.87B6.15121 CrossRef

20.

Finkelstein, R., Rabino, G., Mashiah, T., Bar-El, Y., Adler, Z., Kertzman, V.: Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123, 326–332 (2002). doi:10.1067/mtc.2002.119698 CrossRef

21.

Kitzis, M., Branger, C., Andreassian, B.: Antimicrobial prophylaxis with vancomycin a comparative study in vascular surgery. Interscience Conference on Antimicrobial Agents and Chemotherapy. Program and abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, 254. (1991)

22.

Niederman, M.S.: Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit. Care. Med. 29 Suppl (4), N114–N120 (2001). doi:10.1097/00003246-200104001-00011

23.

Tengs, T.O., Wallace, A.: One thousand health-related quality-of-life estimates. Med Care 38, 583–637 (2000). doi:10.1097/00005650-200006000-00004 CrossRef

24.

National Institute for Clinical Excellence: Guide to the methods of technology appraisal. http://www.nice.org.uk/pdf/TAP_Methods.pdf (2004). Accessed 15 May 2006

25.

Blom, A.W., Taylor, A.H., Pattison, G., Whitehouse, S., Bannister, G.C.: Infection after total hip arthroplasty: the Avon experience. J. Bone Joint. Surg. 85-B, 956–959 (2003)

26.

Kunori, T., Cookson, B., Roberts, J.A., Stone, S., Kibbler, C.: Cost-effectiveness of different MRSA screening methods. J Hosp. Infect. 51, 189–200 (2002). doi:10.1053/jhin.2002.1247 CrossRef

27.

Briggs, A., Goeree, R., Blackhouse, G., O’Brien, B.J.: Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med. Decis. Making 22, 290–308 (2002)

28.

Lodise, T.P., McKinnon, P.S., Rybak, M.: Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect. Control Hosp. Epidemiol 24, 655–661 (2003). doi:10.1086/502269 CrossRef

29.

NHS Centre for Reviews and Dissemination: Antimicrobial prophylaxis in colorectal surgery. Eff. Health Care Bull. 4, 1–8 (1998)

30.

Brisson, M., Edmunds, W.J.: Economic evaluation of vaccination programs: the impact of herd-immunity. Med. Decis. Making 23, 76–82 (2003). doi:10.1177/0272989X02239651 CrossRef

31.

Edmunds, W.J., Medley, G.F., Nokes, D.J.: Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18, 3263–3282 (1999). doi:10.1002/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3 CrossRef

32.

Smith, R.D., Yago, M., Millar, M., Coast, J.: Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. J. Health Econ. 24, 1055–1075 (2005). doi:10.1016/j.jhealeco.2005.02.003 CrossRef

33.

Netten, A., Dennett, J.: Unit costs of community care. ISBN 1092671406. Personal Social Services Research Unit, Kent (2005)

34.

British Medical Association and Royal Pharmaceutical Society of Great Britain: British National Formulary, 50th edn. (2005)

Titel: An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?
verfasst von: Rachel A. Elliott
Helen L. A. Weatherly
Neil S. Hawkins
Gillian Cranny
Duncan Chambers
Lindsey Myers
Alison Eastwood
Mark J. Sculpher
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 1/2010
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-009-0175-0

Springer Medizin

Abstract

Aim

Methods

Results

Discussion

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Cost effectiveness of palivizumab in Spain: an analysis using observational data

On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected

The added value of thorough economic evaluation of telemedicine networks

Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

HTA in Germany: very special and specific